Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 39.35
-0.25 (-0.63%)
Mar 24, 2026, 1:30 PM CST
Pharmosa Biopharm Revenue
In the year 2025, Pharmosa Biopharm had annual revenue of 67.27M TWD, down -59.86%. Pharmosa Biopharm had revenue of 47.59M in the quarter ending December 31, 2025, a decrease of -59.34%.
Revenue
67.27M
Revenue Growth
-59.86%
P/S Ratio
75.99
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.27M | -100.30M | -59.86% |
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Panion & Bf Biotech | 2.06B |
| Medigen Biotechnology | 1.58B |
| BioGend Therapeutics | 222.34M |
| OBI Pharma | 58.58M |
| UnicoCell Biomed | 30.10M |
| AnnJi Pharmaceutical | 23.85M |
| Locus Cell | 5.18M |